There is no 100% consensus for reform in the US
Although there is much talk of US patent reform at the moment, it is worth remembering that not everyone is keen for it to happen. This blog has already had a look at the differences that exist between the large high-tech and pharma companies over…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.